Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Graham R Foster

Showing results (91-100 of 191) with videos related to

Pageof 20
Sort By:
PLOS Global Public Health|April 6, 2026
Correction: Hepatitis C virus cascade of care among adults in Sindh province, Pakistan: Findings from 2019-2020 household sero-surveyTesfa Sewunet Alamneh, Josephine G Walker, Aaron G Lim, et al.
PLOS Global Public Health|July 8, 2025
Hepatitis C virus cascade of care among adults in Sindh province, Pakistan: Findings from 2019-2020 household sero-surveyTesfa Sewunet Alamneh, Josephine G Walker, Aaron G Lim, et al.
Journal of Medical Virology|March 18, 2017
SB 9200, a novel agonist of innate immunity, shows potent antiviral activity against resistant HCV variantsMeleri Jones, Morven E Cunningham, Peter Wing, et al.
AIDS (London, England)|January 29, 2014
Modeling the impact of early antiretroviral therapy for adults coinfected with HIV and hepatitis B or C in South AfricaNatasha K Martin, Angela Devine, Jeffrey W Eaton, et al.
Infectious Diseases and Therapy|May 7, 2017
Chronic Hepatitis C Treatment in Patients with Drug Injection History: Findings of the INTEGRATE Prospective, Observational StudyGeert Robaeys, Stefan Christensen, Damien Lucidarme, et al.
Journal of Hepatology|June 25, 2017
Safety of the 2D/3D direct-acting antiviral regimen in HCV-induced Child-Pugh A cirrhosis - A pooled analysisFred Poordad, David R Nelson, Jordan J Feld, et al.
Journal of Viral Hepatitis|February 6, 2023
The tolerability of sofosbuvir/velpatasvir for 12 weeks in patients treated in the ASTRAL 1, 2 and 3 studies: A pooled safety analysisIra M Jacobson, Stefan Bourgeois, Phillipe Mathurin, et al.
Alimentary Pharmacology & Therapeutics|June 1, 2019
The association between hepatocellular carcinoma and direct-acting anti-viral treatment in patients with decompensated cirrhosisAli Jibran Mecci, Polychronis Kemos, Clifford Leen, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 22, 2004
IFN-alpha subtypes differentially affect human T cell motilityGraham R Foster, Siti H Masri, Rachel David, et al.
Frontline Gastroenterology|March 29, 2018
Non-invasive markers of liver fibrosis in fatty liver disease are unreliable in people of South Asian descentSampath De Silva, Wenhao Li, Polychronis Kemos, et al.
Pageof 20

Showing results (91-100 of 191) with videos related to

Sort By:
Pageof 20
PLOS Global Public Health|April 6, 2026
Correction: Hepatitis C virus cascade of care among adults in Sindh province, Pakistan: Findings from 2019-2020 household sero-surveyTesfa Sewunet Alamneh, Josephine G Walker, Aaron G Lim, et al.
PLOS Global Public Health|July 8, 2025
Hepatitis C virus cascade of care among adults in Sindh province, Pakistan: Findings from 2019-2020 household sero-surveyTesfa Sewunet Alamneh, Josephine G Walker, Aaron G Lim, et al.
Journal of Medical Virology|March 18, 2017
SB 9200, a novel agonist of innate immunity, shows potent antiviral activity against resistant HCV variantsMeleri Jones, Morven E Cunningham, Peter Wing, et al.
AIDS (London, England)|January 29, 2014
Modeling the impact of early antiretroviral therapy for adults coinfected with HIV and hepatitis B or C in South AfricaNatasha K Martin, Angela Devine, Jeffrey W Eaton, et al.
Infectious Diseases and Therapy|May 7, 2017
Chronic Hepatitis C Treatment in Patients with Drug Injection History: Findings of the INTEGRATE Prospective, Observational StudyGeert Robaeys, Stefan Christensen, Damien Lucidarme, et al.
Journal of Hepatology|June 25, 2017
Safety of the 2D/3D direct-acting antiviral regimen in HCV-induced Child-Pugh A cirrhosis - A pooled analysisFred Poordad, David R Nelson, Jordan J Feld, et al.
Journal of Viral Hepatitis|February 6, 2023
The tolerability of sofosbuvir/velpatasvir for 12 weeks in patients treated in the ASTRAL 1, 2 and 3 studies: A pooled safety analysisIra M Jacobson, Stefan Bourgeois, Phillipe Mathurin, et al.
Alimentary Pharmacology & Therapeutics|June 1, 2019
The association between hepatocellular carcinoma and direct-acting anti-viral treatment in patients with decompensated cirrhosisAli Jibran Mecci, Polychronis Kemos, Clifford Leen, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 22, 2004
IFN-alpha subtypes differentially affect human T cell motilityGraham R Foster, Siti H Masri, Rachel David, et al.
Frontline Gastroenterology|March 29, 2018
Non-invasive markers of liver fibrosis in fatty liver disease are unreliable in people of South Asian descentSampath De Silva, Wenhao Li, Polychronis Kemos, et al.
Pageof 20